Medical/Pharmaceuticals
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...
2024-12-09 10:40
2094
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...
2024-12-09 08:42
1923
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. * CS5001 is well tolerated in heavily...
2024-12-09 08:20
3119
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-12-09 08:00
3493
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth. This year, EpiVax expanded the b...
2024-12-07 11:30
4363
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, two prestigious benchmarks jointly compiled by FTSE Russell and the Taiwan S...
2024-12-07 08:57
4062
Another star technology platform of the Sanyou AI-STAL family
——Introducing Sanyou Mrna Mab innovative antibody generation technology platform SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes h...
2024-12-06 18:30
2276
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
SINGAPORE, Dec. 6, 2024 /PRNewswire/ -- IMAGINE AI is the largest calendar event inSingapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potential of AI in healthcare. Hosted at the Marina Bay Sands Expo & Convention Centre, thi...
2024-12-06 10:41
9357
SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center
* SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 * Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ13731...
2024-12-06 09:00
3119
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in theAsia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sens...
2024-12-06 08:07
2904
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...
2024-12-06 07:56
1898
KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024
SYDNEY, Dec. 6, 2024 /PRNewswire/ -- Kaneka Ubiquinol™ has been awarded the
covetedRaw Material Supplier of the Year Award 2024 at the Complementary
Medicines Australia (CMA) Awards, held inSydney this evening.
2024-12-06 06:10
3028
Lunit and Volpara Unveiled Unified Ecosystem at RSNA 2024 to Transform Global Cancer Care
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- At this year's RSNA 2024 Annual Meeting, Lunit (KRX:328130.KQ),...
2024-12-05 22:07
2736
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA
* Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance * Introduces 'Neurophet AQUA AD,' a Total Solution for Alzheimer's Disease Treatment Prescription, at the AI Theater SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution...
2024-12-05 22:00
2385
AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership
HAMILTON, ON, Dec. 5, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, is pleased to announce the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer. Dr. Chattopadhyay brings over 25 years of commercial and technical ...
2024-12-05 22:00
1561
Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.
* First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). * FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devicesthat could provide more effe...
2024-12-05 21:03
2334
LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System
Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings * Replaces time-consuming manual spot checking with continuous, near real-time active patient monitoring * Web-based system displays mult...
2024-12-05 20:00
2049
Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing
EAST RUTHERFORD, N.J., Dec. 5, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly...
2024-12-05 19:00
2519
NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluatingthe efficacy and tolerability of NTC014 ...
2024-12-05 19:00
2525
Cao Thang International Eye Hospital - Marking a footprint on the map of global ophthalmology
HO CHI MINH CITY, Vietnam, Dec. 5, 2024 /PRNewswire/ -- On November 10, 2024, Cao Thang International Eye Hospital was proudly certified to be an official membership with the World Association of Eye Hospitals (WAEH) at the 18th annual meeting which was held inChina. Cao Thang International Eye ...
2024-12-05 18:35
2521
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 311 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35